ECSP10010415A - Compuestos novedosos que son inhibidores de erk - Google Patents

Compuestos novedosos que son inhibidores de erk

Info

Publication number
ECSP10010415A
ECSP10010415A EC2010010415A ECSP10010415A ECSP10010415A EC SP10010415 A ECSP10010415 A EC SP10010415A EC 2010010415 A EC2010010415 A EC 2010010415A EC SP10010415 A ECSP10010415 A EC SP10010415A EC SP10010415 A ECSP10010415 A EC SP10010415A
Authority
EC
Ecuador
Prior art keywords
erk inhibitors
new compounds
formula
compounds
erk
Prior art date
Application number
EC2010010415A
Other languages
English (en)
Spanish (es)
Inventor
Neng Yang Shih
Sunil Paliwal
Hon-Chung Tsui
Alan B Cooper
Jagdish A Desai
Ronald J Doll
Hugh Y Zhu
Gerald W Shipps Jr
James J S Wang
Yongqi Deng
Yang Nan
Sobhana Babu Boga
Abdul-Basit Alhassan
Xiaolei Gao
Liang Zhu
Mehul Patel
Subrahmanyam Gudipati
Xin Yao
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40601237&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP10010415(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of ECSP10010415A publication Critical patent/ECSP10010415A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EC2010010415A 2008-02-21 2010-08-20 Compuestos novedosos que son inhibidores de erk ECSP10010415A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3040708P 2008-02-21 2008-02-21

Publications (1)

Publication Number Publication Date
ECSP10010415A true ECSP10010415A (es) 2010-09-30

Family

ID=40601237

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010010415A ECSP10010415A (es) 2008-02-21 2010-08-20 Compuestos novedosos que son inhibidores de erk

Country Status (23)

Country Link
US (1) US8716483B2 (esLanguage)
EP (1) EP2260031B1 (esLanguage)
JP (1) JP5276676B2 (esLanguage)
KR (1) KR20100117123A (esLanguage)
CN (1) CN102015693B (esLanguage)
AR (1) AR070460A1 (esLanguage)
AU (1) AU2009215534B8 (esLanguage)
BR (1) BRPI0908120A8 (esLanguage)
CA (1) CA2714479A1 (esLanguage)
CL (1) CL2009000394A1 (esLanguage)
CO (1) CO6300939A2 (esLanguage)
EC (1) ECSP10010415A (esLanguage)
ES (1) ES2556353T3 (esLanguage)
IL (1) IL207530A (esLanguage)
MX (1) MX2010009268A (esLanguage)
MY (1) MY152271A (esLanguage)
NZ (1) NZ587504A (esLanguage)
PE (1) PE20091491A1 (esLanguage)
RU (1) RU2525389C2 (esLanguage)
SG (1) SG188179A1 (esLanguage)
TW (1) TWI398441B (esLanguage)
WO (1) WO2009105500A1 (esLanguage)
ZA (2) ZA201005909B (esLanguage)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
CN101415674A (zh) 2006-02-16 2009-04-22 先灵公司 作为erk抑制剂的吡咯烷衍生物
US8586543B2 (en) 2008-08-19 2013-11-19 Merck Sharp & Dohme Corp. IL-8 biomarker for monitoring cancer treatment with certain ERK inhibitors
US9229008B2 (en) 2008-08-19 2016-01-05 Merck Sharp & Dohme Corp. IL-8 level as a determinant of responsivity of a cancer to treatment
WO2011002887A1 (en) 2009-07-02 2011-01-06 Schering Corporation FUSED TRICYCLIC COMPOUNDS AS NOVEL mTOR INHIBITORS
US8658651B2 (en) 2009-09-30 2014-02-25 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
WO2011163330A1 (en) * 2010-06-24 2011-12-29 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012052412A1 (de) 2010-10-22 2012-04-26 Bayer Cropscience Ag Neue heterocylische verbindungen als schädlingsbekämpfungsmittel
WO2012068148A1 (en) * 2010-11-16 2012-05-24 Medimmune, Llc Regimens for treatments using anti-igf antibodies
US9000209B2 (en) 2011-07-22 2015-04-07 Iowa State University Research Foundation, Inc. Method of regioselective synthesis of substituted benzoates
ES2857649T3 (es) 2012-03-01 2021-09-29 Array Biopharma Inc Inhibidores de serina/treonina cinasa
US20150141470A1 (en) 2012-05-08 2015-05-21 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
US9434695B2 (en) 2012-07-18 2016-09-06 Sunshine Lake Pharma Co., Ltd Nitrogenous heterocyclic derivatives and their application in drugs
WO2014052566A1 (en) * 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
JP6280554B2 (ja) * 2012-09-28 2018-02-14 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｅｒｋ阻害剤である新規化合物
AR095365A1 (es) * 2013-03-13 2015-10-14 Hoffmann La Roche Procedimiento para preparar compuestos benzoxazepina
US8871966B2 (en) 2013-03-15 2014-10-28 Iowa State University Research Foundation, Inc. Regiospecific synthesis of terephthalates
CN105636586B (zh) 2013-10-03 2018-05-29 库拉肿瘤学公司 Erk抑制剂及使用方法
EP3143166A4 (en) * 2014-05-16 2018-04-18 University of Massachusetts Treating chronic myelogenous leukemia (cml)
WO2016025639A1 (en) * 2014-08-13 2016-02-18 Celgene Avilomics Research, Inc. Combinations of an erk inhibitor and a chemotherapeutic agent and related methods
WO2016095089A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
WO2016095088A1 (en) 2014-12-15 2016-06-23 Merck Sharp & Dohme Corp. Erk inhibitors
MX2017008077A (es) 2014-12-18 2017-09-28 Merck Sharp & Dohme Composiciones de (s)-n-(3-(6-isopropoxipiridin-3-il)-1h-indazol-5- il)-1-(2-(4-(4-(1-metil-1h-1,2,4-triazol-3-il)fenil)-3,6-dihidrop iridin-1(2h)-il)-2-oxoetil)-3-(metiltio)pirrolidin-3-carboxamida para preparaciones farmaceuticas.
KR20170094795A (ko) * 2014-12-19 2017-08-21 머크 샤프 앤드 돔 코포레이션 제약 제제용 (s)-n-(3-(6-이소프로폭시피리딘-3-일)-1h-인다졸-5-일)-1-(2-(4-(4-(1-메틸-1h-1,2,4-트리아졸-3-일)페닐)-3,6-디히드로피리딘-1(2h)-일)-2-옥소에틸)-3-(메틸티오)피롤리딘-3-카르복사미드 조성물
BR112017021194A2 (pt) 2015-04-03 2019-01-08 Kalyra Pharmaceuticals Inc compostos espirocíclicos
WO2017040362A1 (en) * 2015-09-03 2017-03-09 Merck Sharp & Dohme Corp. Process for preparing spray dried solid dispersions of (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3- (methylthio)pyrrolidine-3-carboxamide for pharmaceutical preparations
CN106432182B (zh) * 2016-09-06 2019-04-30 铜仁学院 特地唑胺中间体的合成方法
CN109020789B (zh) * 2017-06-12 2021-08-13 浙江医药股份有限公司新昌制药厂 一种制备2-甲氧基丙烯的方法
WO2021067266A1 (en) * 2019-10-01 2021-04-08 Recurium Ip Holdings, Llc Pyrrolidinyl-based compounds
CN117567338A (zh) 2019-10-09 2024-02-20 拜耳公司 作为农药的新的杂芳基三唑化合物
CA3160899C (en) 2019-12-06 2024-04-16 Medshine Discovery Inc. Spiro compound serving as erk inhibitor, and application thereof

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2306108A (en) 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
JP2000508335A (ja) 1996-05-30 2000-07-04 メルク エンド カンパニー インコーポレーテッド 癌の治療方法
GB2323845A (en) 1997-03-31 1998-10-07 Merck & Co Inc MEK inhibiting lactones
WO1999003498A1 (en) 1997-07-18 1999-01-28 Novo Nordisk A/S USE OF FVIIa OR FVIIai FOR THE TREATMENT OF ADVERSE CONDITIONS RELATED TO THE FVIIa MEDIATED INTRACELLULAR SIGNALLING PATHWAY
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
AU2001236720A1 (en) 2000-02-05 2001-08-14 Bemis, Guy Compositions useful as inhibitors of erk
AU782775B2 (en) 2000-02-05 2005-08-25 Vertex Pharmaceuticals Incorporated Pyrazole compositions useful as inhibitors of ERK
BR0109188A (pt) 2000-03-15 2003-03-18 Warner Lambert Co Diarilaminas 5-amida substituìdas como inibidores de mex
TWI310684B (en) 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
US7211594B2 (en) * 2000-07-31 2007-05-01 Signal Pharmaceuticals, Llc Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
NZ525016A (en) 2000-09-15 2004-10-29 Vertex Pharma Isoxazoles and their use as inhibitors of ERK
CA2422367C (en) 2000-09-15 2010-05-18 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
JP2004533989A (ja) * 2000-11-20 2004-11-11 サイオス インコーポレイテッド ｐ３８キナーゼのピペリジン／ピペラジン型阻害剤
WO2002059111A2 (en) 2000-12-21 2002-08-01 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MY130778A (en) 2001-02-09 2007-07-31 Vertex Pharma Heterocyclic inhibitiors of erk2 and uses thereof
KR20040007497A (ko) * 2001-04-16 2004-01-24 에자이 가부시키가이샤 신규 1ｈ-인다졸 화합물
JP2004538266A (ja) 2001-04-27 2004-12-24 バーテックス　ファーマシューティカルズ　インコーポレイテッド ピラゾール由来のキナーゼインヒビター
CA2445568A1 (en) 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Triazole-derived kinase inhibitors and uses thereof
MXPA04001088A (es) 2001-08-03 2004-05-20 Vertex Pharma Derivados de pirazol como inhibidores de cinasa y uso de los mismos.
JP4357295B2 (ja) 2001-08-03 2009-11-04 バーテックス ファーマシューティカルズ インコーポレイテッド ピラゾール誘導キナーゼインヒビターとその使用
CA2463101A1 (en) 2001-10-23 2003-05-01 Applied Research Systems Ars Holding N.V. Azole derivatives and pharmaceutical compositions containing them
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
WO2003091246A1 (en) 2002-04-26 2003-11-06 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
WO2003099212A2 (en) 2002-05-24 2003-12-04 The University Of Utah Research Foundation Mitogen activated protein kinase inhibitor compositions for lymphoma therapy
CA2482838A1 (en) * 2002-05-31 2003-12-11 Eisai Co., Ltd. Pyrazole compounds and pharmaceutical compositions containing the compound
US7205308B2 (en) 2002-09-04 2007-04-17 Schering Corporation Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
MXPA05003058A (es) 2002-09-19 2005-05-27 Schering Corp Nuevas imidazopiridinas como inhibidores de cinasa dependientes de ciclina.
JP4808154B2 (ja) 2003-03-13 2011-11-02 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼインヒビターとして有用な組成物
GB2400101A (en) 2003-03-28 2004-10-06 Biofocus Discovery Ltd Compounds capable of binding to the active site of protein kinases
WO2005002673A1 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
CA2546360A1 (en) * 2003-11-19 2005-06-09 Signal Pharmaceuticals, Llc Methods of treating diseases and disorders by targeting multiple kinases
EP1715871A1 (en) 2003-12-22 2006-11-02 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
US7462612B2 (en) 2004-03-26 2008-12-09 Vertex Pharmaceuticals Incorporated Pyridine inhibitors of ERK2 and uses thereof
WO2005100338A1 (en) 2004-04-13 2005-10-27 Astex Therapeutics Limited 5-morpholinylmethylthiophenyl pharmaceutial compounds as p38 map kinase modulators
ZA200610163B (en) 2004-05-14 2008-02-27 Vertex Pharma Prodrugs of pyrrolylpyrimidine ERK protein kinase inhibitors
US7354939B2 (en) 2004-05-14 2008-04-08 Vertex Pharmaceuticals Incorporated Pyrrole inhibitors of ERK protein kinase, synthesis thereof and intermediates thereto
WO2006040569A1 (en) 2004-10-14 2006-04-20 Astex Therapeutics Limited Thiophene amide compounds for use in the treatment or prophylaxis of cancers
EP1833820A1 (en) 2004-12-23 2007-09-19 Vertex Pharmaceuticals Incorporated Selective inhibitors of erk protein kinase and uses therof
CN100377868C (zh) * 2005-03-24 2008-04-02 中国科学院物理研究所 用于磁性/非磁性/磁性多层薄膜的核心复合膜及其用途
WO2006136008A1 (en) 2005-05-24 2006-12-28 University Health Network Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer
US8217042B2 (en) * 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
US8546404B2 (en) * 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
RS51981B (sr) * 2005-12-13 2012-02-29 Schering Corporation Policiklični derivati indazola koji su inhibitori erk
CN101415674A (zh) * 2006-02-16 2009-04-22 先灵公司 作为erk抑制剂的吡咯烷衍生物
EP2260869A3 (en) * 2006-04-20 2011-03-23 Takeda Pharmaceutical Company Limited Pharmaceutical product
US7601852B2 (en) * 2006-05-11 2009-10-13 Kosan Biosciences Incorporated Macrocyclic kinase inhibitors
CN101595107A (zh) * 2006-06-30 2009-12-02 先灵公司 能提高p53活性的有取代哌啶及其用途
US7671832B2 (en) * 2006-07-10 2010-03-02 Philips Lumileds Lighting Company, Llc Multi-colored LED backlight with color-compensated clusters near edge
EP2954900A1 (en) 2007-03-28 2015-12-16 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
CL2008001633A1 (es) 2007-06-05 2008-12-12 Schering Corp Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
MX2009013213A (es) 2007-06-08 2010-03-30 Abbott Lab Indazoles 5-sustituidos 5-heteroarilo como inhibidores de cinasa.
US20110038876A1 (en) 2007-06-18 2011-02-17 Robert Sun Heterocyclic compounds and use thereof as erk inhibitors
US8658651B2 (en) 2009-09-30 2014-02-25 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors

Also Published As

Publication number Publication date
JP5276676B2 (ja) 2013-08-28
CL2009000394A1 (es) 2011-02-11
CN102015693B (zh) 2014-10-29
NZ587504A (en) 2012-09-28
RU2525389C2 (ru) 2014-08-10
PE20091491A1 (es) 2009-09-25
JP2011513225A (ja) 2011-04-28
IL207530A0 (en) 2010-12-30
EP2260031B1 (en) 2015-10-07
CN102015693A (zh) 2011-04-13
SG188179A1 (en) 2013-03-28
US20110189192A1 (en) 2011-08-04
WO2009105500A1 (en) 2009-08-27
KR20100117123A (ko) 2010-11-02
MY152271A (en) 2014-09-15
AU2009215534A8 (en) 2014-07-10
AU2009215534B8 (en) 2014-07-10
BRPI0908120A8 (pt) 2017-10-24
IL207530A (en) 2014-08-31
TW200948799A (en) 2009-12-01
AR070460A1 (es) 2010-04-07
ZA201400396B (en) 2014-12-23
EP2260031A1 (en) 2010-12-15
AU2009215534A1 (en) 2009-08-27
ZA201005909B (en) 2014-03-26
ES2556353T3 (es) 2016-01-15
CO6300939A2 (es) 2011-07-21
RU2010138635A (ru) 2012-03-27
MX2010009268A (es) 2010-09-14
AU2009215534A2 (en) 2010-12-23
TWI398441B (zh) 2013-06-11
BRPI0908120A2 (esLanguage) 2017-08-22
AU2009215534B2 (en) 2014-06-26
CA2714479A1 (en) 2009-08-27
ES2556353T8 (es) 2017-10-13
US8716483B2 (en) 2014-05-06

Similar Documents

Publication Publication Date Title
ECSP10010415A (es) Compuestos novedosos que son inhibidores de erk
UY31774A (es) Compuestos de 2-pirimidin-5- ilcarboxamida sustituidos
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
CL2022000093A1 (es) Imidazopirimidinas como inhibidores de eed y uso de estas
ECSP19051352A (es) Inhibidores selectivos de jak1
SV2010003598A (es) Derivados de tiazol usados como inhibidores de pi 3-cinasa
CR20110579A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750
NI201200132A (es) Derivados de arilmetoxi isoindolina y composiciones que los comprenden y metodos para utilizar los mismos
MX2015011311A (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y analogos del mismo como inhibidores de atotaxina.
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
UY31524A1 (es) Nuevos compuestos 010
ECSP099781A (es) Novedosos compuestos que son inhibidores de erk
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
UY32049A (es) Inhibidores de cmet
DOP2014000036A (es) Compuestos de piridazinona y su uso como inhibidores daao
DOP2009000242A (es) Compuestos de pirido [2,3-d] pirimidina-7-ona como inhibidores de pi3k-alfa para el tratamiento del cancer
UY30912A1 (es) Derivados de 4-pirazol amidas conteniendo carboxi, sales farmacéuticamente aceptables de los mismo, composiciones farmacéuticas conteniéndolos, procesos de preparacion y uso.
ECSP089019A (es) Inhibidores de sulfonamida tricíclicos, fusionados del gama secretasa
AR078278A1 (es) Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro.
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
CL2023002486A1 (es) Compuestos heterocíclicos como inhibidores de delta-5 desaturasa y métodos de uso
CR11860A (es) Derivados de dibenzotiazepina y sus usos - 424
UY32954A (es) PIRIMIDINAS SUSTITUIDAS CON ADAMANTILIMINOCARBONILO COMO INHIBIDORES DE 11-ß-HSD1 826?.
UY29804A1 (es) Quinolinas de alquilnitrilo
ECSP13012372A (es) Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.